---
category: news
title: "Transgene starts trials of ‘digital’ cancer vaccine with NEC"
excerpt: "The French biotech is partnering with artificial intelligence (AI) specialist NEC on the new programme – called TG4050 ... who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy. It was also given a green light for a trial in head and neck cancer by the UK Medicines and Healthcare ..."
publishedDateTime: 2020-01-07T13:20:00Z
sourceUrl: https://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
type: article
quality: 24
heat: 24
published: false

provider:
  name: pharmaphorum.com
  domain: pharmaphorum.com

topics:
  - AI
  - AI in Healthcare

images:
  - url: https://www.bing.com/th?id=ON.3E4F78E119EB7DDFC3E305E5A0A6A184
    width: 700
    height: 467
    title: "Transgene starts trials of ‘digital’ cancer vaccine with NEC"

related:
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "\"As each patient's cancer is unique, we have developed a therapy that turns their solid tumor's genetic signature into a ... Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow this ..."
    publishedDateTime: 2020-01-06T23:00:00Z
    sourceUrl: https://www.benzinga.com/pressreleases/20/01/b15081336/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-ai-powered-cancer-vaccine-for-ovarian-a
    ampUrl: https://amp.benzinga.com/amp/content/15081336
    cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15081336
    type: article
    provider:
      name: Benzinga.com
      domain: benzinga.com
    quality: 14
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "capabilities - Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations - First patients enrolled in two Phase 1 trials at the Mayo Clinic and Toulouse Oncopole TOKYO,"
    publishedDateTime: 2020-01-07T02:06:00Z
    sourceUrl: https://www.benzinga.com/pressreleases/20/01/a15081848/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-ai-powered-cancer-vaccine-for-ovarian-a
    ampUrl: https://amp.benzinga.com/amp/content/15081848
    cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15081848
    type: article
    provider:
      name: Benzinga.com
      domain: benzinga.com
    quality: 14
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "\"As each patient's cancer is unique, we have developed a therapy that turns their solid tumor's genetic signature into a ... Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow this ..."
    publishedDateTime: 2020-01-07T05:30:00Z
    sourceUrl: https://www.benzinga.com/pressreleases/20/01/b15082025/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-individualized-ai-powered-cancer-vaccin
    ampUrl: https://amp.benzinga.com/amp/content/15082025
    cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15082025
    type: article
    provider:
      name: Benzinga.com
      domain: benzinga.com
    quality: 6

secured: "IjgeSJ3voXPWezmaUt1WS66oSciQjGTMyeBQwRjxQ85cPDg4XsH5O1+gVfN8FMxlkNAjtslpgjdoFu6Xg1PlEZCBOmyvQYnwP+HOsS4VlGHd1aFSi2EKD/+ZDhDq3HIRFDuZWZrW/JZvuscQcSFgjefp8Bc2JR5bw6k5TBYHm49cVz+4IKYyW/2ejeCb7xzcow75fxQybuyflwxOHoBK5ZcJQ3Yh9pH+lL2UYFTigobM3z7n6peas432cnNm/3r4wRcWU8Q3NxhsGKu5PTQmlw==;4/rBVIoOjPd34WZLV3yjtA=="
---

